- Home
- AIHS vs NEUP Comparison
AIHS vs NEUP Comparison
Compare AIHS & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIHS
- NEUP
- Stock Information
- Founded
- AIHS 2014
- NEUP 1996
- Country
- AIHS China
- NEUP United States
- Employees
- AIHS N/A
- NEUP N/A
- Industry
- AIHS Finance: Consumer Services
- NEUP
- Sector
- AIHS Finance
- NEUP
- Exchange
- AIHS Nasdaq
- NEUP Nasdaq
- Market Cap
- AIHS 11.9M
- NEUP 12.7M
- IPO Year
- AIHS 2018
- NEUP N/A
- Fundamental
- Price
- AIHS $0.32
- NEUP $7.01
- Analyst Decision
- AIHS
- NEUP Strong Buy
- Analyst Count
- AIHS 0
- NEUP 1
- Target Price
- AIHS N/A
- NEUP $21.00
- AVG Volume (30 Days)
- AIHS 4.2M
- NEUP 22.3K
- Earning Date
- AIHS 08-13-2025
- NEUP 08-15-2025
- Dividend Yield
- AIHS N/A
- NEUP N/A
- EPS Growth
- AIHS N/A
- NEUP N/A
- EPS
- AIHS N/A
- NEUP 0.00
- Revenue
- AIHS $5,878,700.00
- NEUP $15,662,715.00
- Revenue This Year
- AIHS N/A
- NEUP N/A
- Revenue Next Year
- AIHS N/A
- NEUP N/A
- P/E Ratio
- AIHS N/A
- NEUP $4,149.50
- Revenue Growth
- AIHS 12.21
- NEUP N/A
- 52 Week Low
- AIHS $0.26
- NEUP $2.90
- 52 Week High
- AIHS $1.70
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- AIHS 30.64
- NEUP N/A
- Support Level
- AIHS $0.29
- NEUP N/A
- Resistance Level
- AIHS $0.35
- NEUP N/A
- Average True Range (ATR)
- AIHS 0.16
- NEUP 0.00
- MACD
- AIHS -0.06
- NEUP 0.00
- Stochastic Oscillator
- AIHS 3.70
- NEUP 0.00
About AIHS Senmiao Technology Limited
Senmiao Technology Ltd is a holding company. The company's operating segment includes Automobile Transaction and Related Services focusing on the online ride-hailing industry in the People's Republic of China and Online ride-hailing platform Services through its own platform, Xixingtianxia. It generates maximum revenue from the Automobile Transaction and Related Services segment. Geographically, it derives revenue from China.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.